These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
170 related articles for article (PubMed ID: 23457619)
1. MADD knock-down enhances doxorubicin and TRAIL induced apoptosis in breast cancer cells. Turner A; Li LC; Pilli T; Qian L; Wiley EL; Setty S; Christov K; Ganesh L; Maker AV; Li P; Kanteti P; Das Gupta TK; Prabhakar BS PLoS One; 2013; 8(2):e56817. PubMed ID: 23457619 [TBL] [Abstract][Full Text] [Related]
2. Down-modulation of expression, or dephosphorylation, of IG20/MADD in tumor necrosis factor-related apoptosis-inducing ligand-resistant thyroid cancer cells makes them susceptible to treatment with this ligand. Li LC; Jayarama S; Pilli T; Qian L; Pacini F; Prabhakar BS Thyroid; 2013 Jan; 23(1):70-8. PubMed ID: 22998497 [TBL] [Abstract][Full Text] [Related]
3. TRAIL suppresses human breast cancer cell migration via MADD/CXCR7. Wang R; Li JC Asian Pac J Cancer Prev; 2015; 16(7):2751-6. PubMed ID: 25854358 [TBL] [Abstract][Full Text] [Related]
4. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer. Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276 [TBL] [Abstract][Full Text] [Related]
5. MADD/DENN splice variant of the IG20 gene is a negative regulator of caspase-8 activation. Knockdown enhances TRAIL-induced apoptosis of cancer cells. Mulherkar N; Prasad KV; Prabhakar BS J Biol Chem; 2007 Apr; 282(16):11715-21. PubMed ID: 17314102 [TBL] [Abstract][Full Text] [Related]
6. Akt-phosphorylated mitogen-activated kinase-activating death domain protein (MADD) inhibits TRAIL-induced apoptosis by blocking Fas-associated death domain (FADD) association with death receptor 4. Li P; Jayarama S; Ganesh L; Mordi D; Carr R; Kanteti P; Hay N; Prabhakar BS J Biol Chem; 2010 Jul; 285(29):22713-22. PubMed ID: 20484047 [TBL] [Abstract][Full Text] [Related]
7. Knockdown of MADD and c-FLIP overcomes resistance to TRAIL-induced apoptosis in ovarian cancer cells. Li LC; Jayaram S; Ganesh L; Qian L; Rotmensch J; Maker AV; Prabhakar BS Am J Obstet Gynecol; 2011 Oct; 205(4):362.e12-25. PubMed ID: 21855847 [TBL] [Abstract][Full Text] [Related]
9. MADD, a splice variant of IG20, is indispensable for MAPK activation and protection against apoptosis upon tumor necrosis factor-alpha treatment. Kurada BRVVSN; Li LC; Mulherkar N; Subramanian M; Prasad KV; Prabhakar BS J Biol Chem; 2009 May; 284(20):13533-13541. PubMed ID: 19289468 [TBL] [Abstract][Full Text] [Related]
10. Roscovitine sensitizes breast cancer cells to TRAIL-induced apoptosis through a pleiotropic mechanism. Ortiz-Ferrón G; Yerbes R; Eramo A; López-Pérez AI; De Maria R; López-Rivas A Cell Res; 2008 Jun; 18(6):664-76. PubMed ID: 18458681 [TBL] [Abstract][Full Text] [Related]
11. MADD promotes the survival of human lung adenocarcinoma cells by inhibiting apoptosis. Bi W; Wei Y; Wu J; Sun G; Guo Y; Zhang Q; Dong L Oncol Rep; 2013 Apr; 29(4):1533-9. PubMed ID: 23443411 [TBL] [Abstract][Full Text] [Related]
12. IG20 (MADD splice variant-5), a proapoptotic protein, interacts with DR4/DR5 and enhances TRAIL-induced apoptosis by increasing recruitment of FADD and caspase-8 to the DISC. Ramaswamy M; Efimova EV; Martinez O; Mulherkar NU; Singh SP; Prabhakar BS Oncogene; 2004 Aug; 23(36):6083-94. PubMed ID: 15208670 [TBL] [Abstract][Full Text] [Related]
13. MADD is a downstream target of PTEN in triggering apoptosis. Jayarama S; Li LC; Ganesh L; Mardi D; Kanteti P; Hay N; Li P; Prabhakar BS J Cell Biochem; 2014 Feb; 115(2):261-70. PubMed ID: 24038283 [TBL] [Abstract][Full Text] [Related]
14. [Expression of MADD in lung adenocarcinoma tissues and its effects on proliferation and apoptosis of lung adenocarcinoma A549 cells]. Wei YP; Wu JX; Guo YF; Sun GY; Zhang Q; Bi WX; Dong L Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi; 2012 Apr; 28(4):354-7. PubMed ID: 22482404 [TBL] [Abstract][Full Text] [Related]
15. MADD/DENN splice variant of the IG20 gene is necessary and sufficient for cancer cell survival. Mulherkar N; Ramaswamy M; Mordi DC; Prabhakar BS Oncogene; 2006 Oct; 25(47):6252-61. PubMed ID: 16682944 [TBL] [Abstract][Full Text] [Related]
16. WEE1 inhibition sensitizes basal breast cancer cells to TRAIL-induced apoptosis. Garimella SV; Rocca A; Lipkowitz S Mol Cancer Res; 2012 Jan; 10(1):75-85. PubMed ID: 22112940 [TBL] [Abstract][Full Text] [Related]
17. MADD Expression in Lung Adenocarcinoma and its Impact on Proliferation and Apoptosis of Lung Adenocarcinoma Cells. Ye B; Zhong F; Yu G; Lou H; Hu J Comb Chem High Throughput Screen; 2019; 22(3):207-215. PubMed ID: 30947659 [TBL] [Abstract][Full Text] [Related]
18. Regulation of apoptosis and caspase-8 expression in neuroblastoma cells by isoforms of the IG20 gene. Li LC; Sheng JR; Mulherkar N; Prabhakar BS; Meriggioli MN Cancer Res; 2008 Sep; 68(18):7352-61. PubMed ID: 18794122 [TBL] [Abstract][Full Text] [Related]
19. IG20, in contrast to DENN-SV, (MADD splice variants) suppresses tumor cell survival, and enhances their susceptibility to apoptosis and cancer drugs. Efimova EV; Al-Zoubi AM; Martinez O; Kaithamana S; Lu S; Arima T; Prabhakar BS Oncogene; 2004 Feb; 23(5):1076-87. PubMed ID: 14716293 [TBL] [Abstract][Full Text] [Related]
20. Loss of MADD expression inhibits cellular growth and metastasis in anaplastic thyroid cancer. Saini S; Sripada L; Tulla K; Kumar P; Yue F; Kunda N; Maker AV; Prabhakar BS Cell Death Dis; 2019 Feb; 10(2):145. PubMed ID: 30760700 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]